Summary
Global Markets Direct’s, ‘Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2016’, provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
- The report reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics and enlists all their major and minor projects
- The report assesses Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
3SBio Inc.
Amgen Inc.
Baxalta Incorporated
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Hansa Medical AB
Immunomedics, Inc.
Intas Pharmaceuticals Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Merck & Co., Inc.
Momenta Pharmaceuticals, Inc.
Novartis AG
Pfizer Inc.
PhytoHealth Corporation
Protalex, Inc.
Rigel Pharmaceuticals, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview 9
Therapeutics Development 10
Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview 10
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Development by Companies 11
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Development by Companies 16
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development 18
3SBio Inc. 18
Amgen Inc. 19
Baxalta Incorporated 20
Boehringer Ingelheim GmbH 21
Bristol-Myers Squibb Company 22
Eisai Co., Ltd. 23
Hansa Medical AB 24
Immunomedics, Inc. 25
Intas Pharmaceuticals Ltd. 26
Jiangsu Hengrui Medicine Co., Ltd. 27
Merck & Co., Inc. 28
Momenta Pharmaceuticals, Inc. 29
Novartis AG 30
Pfizer Inc. 31
PhytoHealth Corporation 32
Protalex, Inc. 33
Rigel Pharmaceuticals, Inc. 34
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
Antibody for Autoimmune Disorders and Inflammation - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
avatrombopag - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
BI-655064 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
BMS-986004 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
eltrombopag olamine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
eltrombopag olamine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
fostamatinib disodium - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
GL-2045 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
GSK-2285921 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Hetrombopag Olamine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MK-8723 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
PBF-1509 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
PHN-013 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PRTX-100 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
romiplostim - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
romiplostim biosimilar - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
SM-101 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
thrombopoietin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
veltuzumab - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Recent Pipeline Updates 78
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects 93
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products 94
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones 95
Featured News & Press Releases 95
Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag 95
Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP 95
Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco 96
Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP 97
Jun 11, 2015: Novartis gains FDA approval for Promacta providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder 97
Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade) 98
Dec 22, 2014: GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta) 99
Jul 16, 2014: Rigel Initiates Phase 3 Studies of Fostamatinib in ITP 99
Oct 31, 2013: Kyowa Hakko Kirin Announces Launch Of Nplate In Taiwan 99
Oct 24, 2013: Rigel Provides Update On Oral SYK Inhibitor Fostamatinib 100
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 101
Disclaimer 102
List of Tables
Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2016 10
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Development by Companies, H1 2016 (Contd..1) 17
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc., H1 2016 18
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc., H1 2016 19
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Baxalta Incorporated, H1 2016 20
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 21
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Bristol-Myers Squibb Company, H1 2016 22
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Eisai Co., Ltd., H1 2016 23
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Hansa Medical AB, H1 2016 24
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Immunomedics, Inc., H1 2016 25
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Intas Pharmaceuticals Ltd., H1 2016 26
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 27
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Merck & Co., Inc., H1 2016 28
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 29
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Novartis AG, H1 2016 30
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc., H1 2016 31
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by PhytoHealth Corporation, H1 2016 32
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Protalex, Inc., H1 2016 33
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals, Inc., H1 2016 34
Assessment by Monotherapy Products, H1 2016 35
Number of Products by Stage and Target, H1 2016 37
Number of Products by Stage and Mechanism of Action, H1 2016 39
Number of Products by Stage and Route of Administration, H1 2016 41
Number of Products by Stage and Molecule Type, H1 2016 43
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics - Recent Pipeline Updates, H1 2016 78
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H1 2016 93
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H1 2016 94
List of Figures
Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 35
Number of Products by Top 10 Targets, H1 2016 36
Number of Products by Stage and Top 10 Targets, H1 2016 36
Number of Products by Top 10 Mechanism of Actions, H1 2016 38
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 38
Number of Products by Routes of Administration, H1 2016 40
Number of Products by Stage and Routes of Administration, H1 2016 40
Number of Products by Molecule Types, H1 2016 42
Number of Products by Stage and Molecule Types, H1 2016 42
